Results 11 to 20 of about 2,710 (195)
Intralenticular Ozurdex® – One Year Later
Case Reports in Ophthalmology, 2017 Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation.
Kathleen A. Regan +3 more
doaj +5 more sources
Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis
Indian Journal of Ophthalmology, 2015 Aims: To report our experiences using Ozurdex, a biodegradable implant, containing 0.7 mg of dexamethasone in the treatment of noninfectious intermediate uveitis. Settings and Design: Retrospective study design.
Swetha Palla +2 more
doaj +4 more sources
Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) [PDF]
Case Reports in Ophthalmological Medicine, 2014 A 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months. Following investigations, she was diagnosed with MacTel type 1 in the right eye.
Mohamed Loutfi +2 more
doaj +2 more sources
Splitting of a Dexamethasone Implant (Ozurdex) following the Injection [PDF]
Case Reports in Ophthalmological Medicine, 2013 In this brief report, we share our observations on a splitted Dexamethasone implant (Ozurdex) which we discovered a week after the injection. It is likely that implant splitting neither changes the efficacy of the implant nor creates a mishap for the patient.
Parlak, Melih +3 more
core +7 more sources
The effects of repeated Ozurdex injections on ocular hypertension
Clinical Ophthalmology, 2018 The purpose of this study was to correlate the degree of ocular hypertension with the number of Ozurdex injections.Intraocular pressure (IOP) fluctuations for a total of 183 injections were studied over a period of at least 12 months. The main indications for treatment were uveitis, diabetic macular edema, and retinal vein occlusion.Results of the ...
Bahadorani,Sepehr +7 more
openaire +6 more sources
Case Reports in Ophthalmology, 2011 Purpose: To report the effective treatment of cystoid macular edema (CME) following complicated cataract surgery (resulting in Irvine-Gass syndrome) with a dexamethasone 0.7-mg (Ozurdex®) intravitreal implant.
Linda M. Meyer, Carl-Ludwig Schönfeld
doaj +2 more sources
Anterior Chamber Dislocation Of Ozurdex Implant: A Case Report [PDF]
Beyoglu Eye Journal, 2018 Anterior chamber dislocation of an Ozurdex (Allergan plc, Dublin, Ireland) implant from the vitreous cavity is unusual. The risk factors for dexamethasone implant migration into the anterior chamber include a defective posterior lens capsule, aphakia, and a prior history of pars plana vitrectomy.
Ertan, Elif +3 more
openaire +5 more sources
A wandering Ozurdex in the anterior chamber
Taiwan Journal of Ophthalmology, 2023 Dexamethasone intravitreal implantation (Ozurdex®, Allergan Inc. Irvine, CA, USA) has been used in the treatment of persistent macular edema (ME) due to various vitreoretinal diseases.
Ching-Tai Chen +2 more
doaj +3 more sources
Oman Journal of Ophthalmology, 2012 Context: Dexamethasone Posterior-Segment Drug Delivery System is a novel, biodegradable, sustained-release drug delivery system (OZURDEX® ) for treatment of macular edema following retinal vein occlusion and posterior uveitis. However, its potential role
Pukhraj Rishi +3 more
doaj +2 more sources
Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis
Graefe's Archive for Clinical and Experimental Ophthalmology, 2015 The purpose of this study was to investigate the safety and effectiveness of an intravitreally injected dexamethasone-containing implant (Ozurdex(®)) in the treatment of uveitis in children.The study group included ten patients (14 eyes) aged 6.5-15 years (mean age 12 years) with intermediate or posterior uveitis who were treated with the Ozurdex ...
Ruti, Sella +5 more
openaire +3 more sources